1430473-02-1Relevant articles and documents
The discovery of orally bioavailable tyrosine threonine kinase (TTK) inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as anticancer agents
Liu, Yong,Lang, Yunhui,Patel, Narendra Kumar,Ng, Grace,Laufer, Radoslaw,Li, Sze-Wan,Edwards, Louise,Forrest, Bryan,Sampson, Peter B.,Feher, Miklos,Ban, Fuqiang,Awrey, Donald E.,Beletskaya, Irina,Mao, Guodong,Hodgson, Richard,Plotnikova, Olga,Qiu, Wei,Chirgadze, Nickolay Y.,Mason, Jacqueline M.,Wei, Xin,Lin, Dan Chi-Chia,Che, Yi,Kiarash, Reza,Madeira, Brian,Fletcher, Graham C.,Mak, Tak W.,Bray, Mark R.,Pauls, Henry W.
supporting information, p. 3366 - 3392 (2015/05/05)
The acetamido and carboxamido substituted 3-(1H-indazol-3-yl)benzenesulfonamides are potent TTK inhibitors. However, they display modest ability to attenuate cancer cell growth; their physicochemical properties, and attendant pharmacokinetic parameters, a
KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME
-
Paragraph 0259, (2014/02/15)
The present teachings provide a compound represented by structural formula (I): or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof.
